Clinical trial · no report yet · Phase 2
NCT03290950
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
- NCT03290950 ↗
- Active, not recruiting
- Memorial Sloan Kettering Cancer Center
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase II Study
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- daratumumab; carfilzomib; lenalidomide; dexamethasone; dexamethasone
- Arms
- Cohort 1 · Experimental
- Cohort 2 · Experimental
- Enrollment
- 69
- Primary outcomes
- Best Overall Response
- Sponsor
- Memorial Sloan Kettering Cancer Center with Janssen Pharmaceuticals
- Start
- Sep 25, 2017
- Primary completion
- May 21, 2025
- Results posted
- Yes
- Registry record
- NCT03290950 · updated May 29, 2026
Publications
linked from the registry- Maura F, Boyle EM, Coffey D, Maclachlan K, Gagler D, Diamond B, Ghamlouch H, Blaney P, Ziccheddu B, Cirrincione A, Chojnacka M, Wang Y, Siegel A, Hoffman JE, Kazandjian D, Hassoun H, Guzman E, Mailankody S, Shah UA, Tan C, Hultcrantz M, Scordo M, Shah GL, Landau H, Chung DJ, Giralt S, Zhang Y, Arbini A, Gao Q, Roshal M, Dogan A, Lesokhin AM, Davies FE, Usmani SZ, Korde N, Morgan GJ, Landgren O. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens. Nat Cancer. 2023 Dec;4(12):1660-1674. doi: 10.1038/s43018-023-00657-1. Epub 2023 Nov 9. PubMed 37945755